<DOC>
	<DOCNO>NCT00301990</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Interleukin-2 may stimulate white blood cell kill tumor cell . Giving bevacizumab together interleukin-2 may kill tumor cell . PURPOSE : This phase II trial study well give bevacizumab together interleukin-2 work treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Bevacizumab Interleukin-2 Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate response , progression-free survival , overall survival patient metastatic renal cell carcinoma ( RCC ) treat bevacizumab high-dose interleukin-2 ( IL-2 ) . Secondary - Compare response survival patient metastatic RCC treat bevacizumab high-dose IL-2 historical data patient treat high-dose IL-2 alone . - Compare toxicity bevacizumab high-dose IL-2 patient metastatic RCC historical data patient treat high-dose IL-2 alone , term number dose IL-2 administer first course therapy , toxicity schedule ninth dose IL-2 , frequency grade III IV unexpected rare toxicity . - Compare time disease progression patient metastatic RCC treat bevacizumab high-dose IL-2 historical data patient treat high-dose IL-2 alone . - Evaluate pharmacokinetics pharmacodynamics bevacizumab high-dose IL-2 course 1 . - Correlate serum vascular endothelial growth factor ( VEGF ) level , DC function , TCR zeta chain expression , arginase arginine level toxicity , response , survival patient treat regimen . - Evaluate utility know prognostic criterion RCC patient clinical outcome . OUTLINE : This multicenter study . Patients stratify accord prognosis ( good v intermediate v poor ) . Patients receive bevacizumab IV 30-90 minute day -13 , 1 , 15 , 29 , 43 , 57 , 71 course 1 day 1 , 15 , 29 , 43 , 57 , 71 course 2 3 . Patients also receive high-dose interleukin-2 every 8 hour day 1-5 15-19 . Treatment repeat every 84 day 3 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 65 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic renal cell carcinoma ( RCC ) predominantly clear cell histology Measurable disease No history tumorrelated hemorrhage No history CNS brain metastasis PATIENT CHARACTERISTICS : Karnofsky performance status ≥ 80 % Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL ( transfusion recombinant erythropoietin growth factor allow ) AST ≤ 2 time upper limit normal ( ULN ) ( 5 time ULN due liver metastasis ) Serum total bilirubin ≤ 2 time ULN ( except patient Gilbert 's disease ) Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min FEV_1 ≥ 2.0 L ≥ 75 % predict Pulmonary function test require patient age 50 significant pulmonary smoking history No history cerebrovascular accident transient ischemic attack No evidence follow cardiac conditions* : Congestive heart failure Symptoms coronary artery disease Myocardial infarction &lt; 6 month prior study entry Serious cardiac arrhythmia Unstable angina NOTE : *Patients &gt; 40 year old previous myocardial infarction &gt; 6 month prior study entry require negative low probability cardiac stress test cardiac ischemia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except nonmelanoma skin cancer noninvasive cancer , cervical carcinoma situ , superficial bladder cancer without local recurrence , breast cancer situ Patients history another invasive malignancy must complete remission ≥ 5 year No positive serology HIV , hepatitis B , hepatitis C No significant comorbid illness , uncontrolled diabetes active infection , would preclude study treatment No history inflammatory bowel disease serious autoimmune disease Thyroiditis rheumatoid arthritis allow No uncontrolled hypertension ( i.e. , blood pressure &gt; 150/100 mm Hg ) Proteinuria ≤ 3+ dipstick OR proteinuria &lt; 2 gm 24hour urine collection Urine protein : creatinine ration &lt; 1.0 No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study entry No significant traumatic injury within past 28 day No serious , nonhealing wound , ulcer , bone fracture No active bleed No history serious hemorrhage , bleed diathesis , underlie coagulopathy No history deep venous thrombosis , clinically significant peripheral vascular disease , thrombotic event PRIOR CONCURRENT THERAPY : No organ allograft At least 4 week since prior radiotherapy surgery recover No prior systemic therapy metastatic RCC No prior bevacizumab interleukin2 At least 2 week since prior steroid No major surgery open biopsy within past 28 day No minor surgical procedure , fine needle aspiration , core biopsy within past 7 day , except central venous catheter placement No concurrent major surgery No concurrent corticosteroid immunosuppressant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
</DOC>